| Identification | Back Directory | [Name]
(BOC-CYS-OH)2 | [CAS]
10389-65-8 | [Synonyms]
BOC-L-CYSTINE
(BOC-CYS-OH)2
(Boc-L-Cys-OH)2
BIS-BOC-L-CYSTINE
N N-BOC-L-CYSTEINE
(Boc-CYS-OH)2, 〉98%
N,N'-Bis-Boc-cystine
N,N’-di-Boc-L-cystine
N,N'-Bis-Boc-L-cystine
BOC-L-CYSTINE extrapure
(BOC-CYS-OH)2 USP/EP/BP
(Boc-Cys-OH)2
(Boc-Cys-OH)2 >=98% (CE)
N,N'-BIS-T-BOC-L-CYSTINE
(Boc-Cys-OH)2 (Disulfide bond)
((Tert-Butoxy)Carbonyl Cys-OH)2
N-ALPHA,N-ALPHA'-DI-BOC-L-CYSTINE
N,N'-Bis(tert-butoxycarbonyl)cystine
N-alpha-t-Butyloxycarbonyl-L-cystine
Nα,Nα'-Bis-Boc-L-cystine≥ 98% (HPLC)
N,N'-bis[tert-butoxycarbonyl]-L-cysteine
N,N''-Bis-(tert-butoxycarbonyl)-L-cystine
N,N'-Bis[(tert-butyloxy)carbonyl]-L-cystine
N-ALPHA,N-ALPHA-BIS-T-BUTYLOXYCARBONYL-L-CYSTINE
Nalpha,Nalpha'-di(tert-butoxycarbonyl)-L-cystine
3,3'-Dithiobis[N-(tert-butoxycarbonyl)-L-alanine]
L-Cystine, N,N'-bis[(1,1-dimethylethoxy)carbonyl]-
(2R)-2-{[(tert-butoxy)carbonyl]amino}-3-{[(2R)-2-{[(tert-butoxy)carbonyl]amino}-2-carboxyethyl]disulfanyl}propanoic acid
3-[[2-carboxy-2-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]ethyl]disulfanyl]-2-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]propanoic acid | [EINECS(EC#)]
233-852-9 | [Molecular Formula]
C16H28N2O8S2 | [MDL Number]
MFCD00038250 | [MOL File]
10389-65-8.mol | [Molecular Weight]
440.53 |
| Chemical Properties | Back Directory | [Melting point ]
140-145 °C | [Boiling point ]
627.4±55.0 °C(Predicted) | [density ]
1.313±0.06 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Sealed in dry,2-8°C | [solubility ]
Acetic Acid (Sparingly) DMSO (Slightly, Sonicated), Methanol (Slightly) | [form ]
Solid | [pka]
3.17±0.10(Predicted) | [color ]
White to Off-White | [Optical Rotation]
[α]20/D 120±3°, c = 2% in acetic acid | [BRN ]
2229312 | [Major Application]
peptide synthesis | [InChIKey]
MHDQAZHYHAOTKR-UWVGGRQHSA-N | [SMILES]
CC(C)(C)OC(=O)N[C@@H](CSSC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C(O)=O |
| Hazard Information | Back Directory | [Chemical Properties]
White powder | [Uses]
N,N''-Di-BOC-L-cystine, can be used for the synthesis of Toll-Like Receptor-2 agonists lipopeptides, which are potential vaccine adjuvants. | [reaction suitability]
reaction type: Boc solid-phase peptide synthesis | [Purification Methods]
Crystallise the cystine derivative from EtOAc by adding hexane [Ferraro pKEst Biochemical Preparations 13 39 1971]. |
|
|